Rome Foundation Releases Clinical Criteria to Better Meet Needs of Patients
November 29, 2021 09:00 ET | Rome Foundation
RALEIGH, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation has published a groundbreaking modification of the Rome IV diagnostic criteria of the Disorders of Gut Brain Interaction (DGBI -...
Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
August 30, 2021 08:19 ET | Biomerica, Inc.
Final patients to compete this double blinded trial by end of October. Top-Line trial results expected by year end.The InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind for...
Biomerica Announces Notice of Allowance for Patent on Product used to Diagnose and Treat Depression
August 11, 2021 08:19 ET | Biomerica, Inc.
Hundreds of millions of people worldwide suffer from depression IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the Japanese Patent Office has...
Vitality New.png
FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug
August 10, 2021 09:00 ET | Vitality Biopharma, Inc
CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic...
Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment
June 15, 2021 08:19 ET | Biomerica, Inc.
IBS is one of the most important gastrointestinal disorders in Mexico, with a prevalence of around 16% [1] (approximately 20 million patients)Broadens InFoods® global patent coverage with recently...
Global Irritable Bowel Syndrome (IBS) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Analysis
June 09, 2021 06:28 ET | Research and Markets
Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome (IBS) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diagnosis (Laboratory Tests, Imaging...
Biomerica Reports Fiscal Year End May 31, 2020 Financial Results
September 01, 2020 08:19 ET | Biomerica, Inc.
Fiscal fourth quarter revenues increase 133.7% over the prior yearFiscal 2020 revenues increase 28.7% over fiscal 2019 New InFoods® patent granted for Singapore IRVINE, Calif., Sept. 01, 2020 ...
Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors
August 31, 2020 08:19 ET | Biomerica, Inc.
IRVINE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced today the retirement of Janet Moore, the Company’s Chief Financial Officer. After many years of...
The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial
June 29, 2020 21:39 ET | Biomerica, Inc.
InFoods® Diagnostic-Guided Therapy is designed to identify patient-specific foods that, when removed from the diet, may alleviate an individual's IBS symptoms Approximately 45 million Americans...
Biomerica Announces $2.0 Million Investment by Palm Global Small Cap Master Fund
February 26, 2020 16:41 ET | Biomerica, Inc.
IRVINE, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) (the “Company” or “Biomerica”) announced today that the Company completed a private placement of $2 million of...